Prostate Specific Antigen News Archive
In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.
A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.
In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
Decreases in use of screening following USPSTF recommendations against routine PSA screening.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
The PLCO trial's conclusion that routine PSA testing does not affect prostate cancer mortality risk could be wrong.
The odds of PSA screening were higher among blacks than non-Hispanic whites.
PSA level declined by an average of 0.68 ng/mL in the treatment group.
Older men whose clinician was a physician trainee had substantially lower prostate-specific antigen (PSA) screening rates.
The proportion of biopsied men who have complications from the procedure rose from 14% to 18% from 2005 to 2014.
This includes less frequent screening and more restrictive biopsy referral criteria.
Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.
Rate of unnecessary screening was 15.7% in men 65 years and older.
Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.
Equal serum prostate-specific antigen and prostate-specific antigen mass despite larger prostates.
A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.
Prostate-specific antigen density, total tumor length are significant predictors.
After, men undergoing prostate needle biopsy more likely to be diagnosed with high-risk disease.
Screening not linked to improved patient survival after transplant; may delay time to listing, transplant.
Researchers say they believe study findings support a hypothesis than ejaculation resulting from sexual intercourse might cause PSA bounce.
Men with a normal PSA upon repeat testing had a 78% lower risk of prostate cancer diagnosis than men with a second abnormal PSA result.
Only 4.5% of Medicare patients on active surveillance or watchful waiting for prostate cancer are monitored as closely as they should be.
The time to PSA progression in men with relapsing or locally advanced PCa was similar with intermittent and continuous androgen deprivation.
PSA doubling time increased from 28 to 76 months in patients performing exercise training.
But whether that's good or bad isn't yet clear
In small study, olaparib targeted gene mutation in men who had failed other therapy.
A year after the federal task force came out against routine PSA screening, diagnoses of low-risk PCa decreased by 38% and continued to fall.
Findings could have implications for active surveillance criteria for African Americans.
Reduction in prostate-specific antigen level in some patients with biochemical recurrence.
Men receiving active surveillance were 24 times more likely to die from causes other than prostate cancer over 15 years.
Giving docetaxel before abiraterone does not improve progression-free and overall survival compared with the reverse sequence.
The technique, with cognitive assistance, identified recurrent tumors in 80% of patients.
A PHI of 82 discriminated between patients with and without biochemical recurrence.
Primary care screening patterns have changed as a result of the USPSTF recommendation.
Biopsies triggered by an abnormal DRE alone were significantly less likely to detect clinically significant prostate cancer than biopsies triggered by an abnormal PSA alone.
Patients with higher PSA, shorter PSA doubling time more likely to have second bone scan.
In a small study of mCRPC patients, the median time on therapy increased by nearly 100 days and PSA declined in some subjects.
Guideline outlines recommended follow-up care for prostate cancer survivors
Just over 41% of patients eligible for active surveillance by European standards were found to have undergraded prostate cancer.
PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.
New study examined the effect of a U.S. Preventive Services Task Force 2012 recommendation against routine PSA screening.
Diagnostic usefulness of magnetic resonance imaging/ultrasound (MRI/US) fusion targeted prostate biopsy optimized in PSA level of 5.2 ng/mL or higher.
Greater PSA increases seen in older men and those with lower baseline testosterone.
PSA levels at day 30 found to predict biochemical relapse risk in men with positive surgical margins.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.
Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
This parameter can identify prostate cancer patients for whom adjuvant radiation therapy after radical prostatectomy may be of no benefit.
PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.
Men diagnosed with low-risk prostate cancer today have lower PSA levels and tumor volume than men 15 years ago.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
Higher circulating tumor cell counts are associated with an increased risk of death.
Trend follows the 2012 release of a U.S. Preventive Services Task Force recommendation against such testing.
Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.
High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.
Additional predictors guide selection of patients for active surveillance programs.
New nomogram could help clinicians and patients make treatment decisions.
TPTPB should be regarded as the gold-standard test in men with two sets of negative TRUS-guided biopsies and rising PSA levels, researchers say.
Texas study shows that PSA screening was ordered for 41% of men aged 75 and older, largely because of decisions by primary-care physicians.
Biopsy-related procedures accounted for much of the cost.
Relying on PSA doubling time from just one year of active surveillance can result in as many as one in five prostate cancer patients being advised to undergo curative treatment that may be unnecessary.
One year of PSA test results can lead to 10%-20% of men being misclassified as having a high risk of prostate cancer progression.
Print- and Web-based tools presenting the benefits and limitations of PSA testing served to help men resolve their own conflicts.
Findings support the notion of a link with sleep or circadian disruption.
Post-PSA intro, big drop in advanced-stage cancers but only modest drop in high Gleason score cancers.
PSA levels below 0.65 ng/mL provide the best sensitivity and specificity (65.2% and 55.5%, respectively) for predicting severe hypogonadism.
Findings based on survey even after informing men about the USPSTF recommendation.
The drug prolonged development of bone metastasis by a median of 7.2 months.
PSA declined by a median of 99.6% and bone mineral density remained stable from baseline to week 25.
Saw palmetto remains the most common herbal treatment for men with LUTS.
Shared decision-making about screening recommended for men aged 55-69 years.
Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.
Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds.
Study reveals no significant association between BMI and prebiopsy PSA, Gleason score, clinical T stage, and D'Amico risk.
Most men with biopsy-detected cancer undergo treatment, regardless of age, comorbidities.
PSA at age 40 to 55 correlates with risk of death or metastasis during 25 to 30 years of follow-up.
New findings provide a rationale for immunotherapy as an early step in sequencing treatment algorithm for mCRPC.
American College of Physicians' new screening guidance committee urges caution
New findings raise questions about PSA screening criteria.
Stopping PSA testing at age 70 may be premature, at least in men with high-risk disease and long life expectancies, researchers conclude.
The survival benefit is limited to men aged 55-69 years at initial screening, large European study finds.
Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results
Much of variation in use of informed decision-making due to physicians' attitudes to screening.
PSA concentrations are higher in men who engage in more sedentary behavior and lower levels of light physical activity, a study found.
Researchers urge prostate biopsies for men with a low neutrophil count and increased serum PSA level.
The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression.
Findings in men with persistently increased serum PSA and previously negative prostate biopsies
Provisional clinical opinion from ASCO suggests benefit for men with longer life expectancy.
Phase 2 trial shows benefit in men with recurrent prostate cancer.
Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting.
PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study.
Renal and Urology News Articles
- Testosterone Prescribing Declining in the US
- FDA Requires Safety Label Changes for Fluoroquinolones
- Development of Clinically Evident Gout: A Closer Look at Elevated Serum Urate Levels
- Robotic Partial Nephrectomy Mostly Superior to Other Surgeries
- AV Access at Hemodialysis Initiation Less Likely Among Women
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)